2023
Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection
Wei J, Patil A, Collings C, Alfajaro M, Liang Y, Cai W, Strine M, Filler R, DeWeirdt P, Hanna R, Menasche B, Ökten A, Peña-Hernández M, Klein J, McNamara A, Rosales R, McGovern B, Luis Rodriguez M, García-Sastre A, White K, Qin Y, Doench J, Yan Q, Iwasaki A, Zwaka T, Qi J, Kadoch C, Wilen C. Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection. Nature Genetics 2023, 55: 471-483. PMID: 36894709, PMCID: PMC10011139, DOI: 10.1038/s41588-023-01307-z.Peer-Reviewed Original ResearchConceptsMSWI/SNF complexesAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionHost-directed therapeutic targetSyndrome coronavirus 2 infectionSARS-CoV-2 infectionSWItch/Sucrose Non-Fermentable (SWI/SNF) chromatinSARS-CoV-2 susceptibilityNon-fermentable (SWI/SNF) chromatinCoronavirus 2 infectionEnzyme 2 (ACE2) expressionSARS-CoV-2 variantsHuman cell typesPrimary human cell typesAirway epithelial cellsDrug-resistant variantsNew drug targetsChromatin accessibilitySNF complexACE2 locusACE2 expressionFactor complexHost determinantsTherapeutic targetConfer resistance
2021
T3 Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies sphingosine kinase 1 as a potential therapeutic target
Reichmann M, Tezera L, Vallejo A, Vukmirovic M, Xiao R, Jogai S, Wilson S, Marshall, Jones, Leslie A, D’Armiento J, Kaminski N, Polak M, Elkington P. T3 Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies sphingosine kinase 1 as a potential therapeutic target. Thorax 2021, 76: a2-a3. DOI: 10.1136/thorax-2021-btsabstracts.3.Peer-Reviewed Original ResearchPotential therapeutic targetTherapeutic targetTB granulomasHost-directed therapeutic targetHuman tuberculosis granulomasImmunopathology of tuberculosisPathological host responsesInflammatory immune responseSphingosine kinase 1 inhibitionInflammatory mediator secretionImmune-related phenomenaDisease-specific mechanismsNew therapeutic approachesHuman TB granulomasDose-dependent mannerKinase 1 inhibitionDunnett's multiple comparison testMultiple comparison testHuman cell culture modelsTB patientsLymph nodesSarcoidosis patientsTB outcomesClinical featuresTuberculosis granulomas
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply